Hohmann E L, Tashjian A H
Endocrinology. 1984 Apr;114(4):1321-7. doi: 10.1210/endo-114-4-1321.
We have previously reported that vasoactive intestinal peptide (VIP) stimulates bone resorption in organ culture via a cAMP-dependent mechanism. Here we describe functional receptors for VIP on a clonal line of human osteosarcoma cells, SaOs-2. SaOs-2 cells respond to VIP with an increase in cAMP. The effect was rapid (2 min) and dose dependent from 0.15-15 nM VIP, with half-maximal stimulation at 1.4 nM. SaOs-2 cells produce prostaglandin E2 (PGE2) and respond to exogenous PGE2 with increases in cAMP approximately one third as great as those induced by VIP. However, the VIP-stimulated increases in cAMP occurred without detectable increases in PGE2 production, and increases in cAMP were unaffected by the cyclooxygenase inhibitor indomethacin. SaOs-2 cells pretreated with VIP for 24 h were significantly less responsive to a second acute challenge with VIP, but retained their ability to respond to PGE2. Similarly, pretreatment with PGE2 induced homologous desensitization to PGE2, but had no effect on the VIP-stimulated increase in cAMP. These patterns of response paralleled those previously described in whole bone in organ culture. Binding studies with [125I]VIP demonstrated specific, saturable, high affinity receptors for VIP on SaOs-2 cells. Scatchard analysis of [125I]VIP binding at 37 C resulted in a curvilinear plot. Analysis based upon the assumption of two independent binding sites gave Kd values of 0.44 and 17 nM for high and low affinity binding sites, respectively. The numbers of high and low affinity sites per cell were determined to be 8,500 and 57,000, respectively. Binding of [125I]VIP was partially inhibited by two related peptides, secretin and PHI-27, but not by PTH, calcitonin or a variety of unrelated peptides. We conclude that the action of VIP on human SaOs-2 cells is similar to that observed in intact mouse calvaria, and that these cells provide a good model for the study of the initial steps of VIP action in bone.
我们之前曾报道,血管活性肠肽(VIP)通过一种依赖cAMP的机制刺激器官培养中的骨吸收。在此,我们描述了人骨肉瘤细胞克隆系SaOs-2上VIP的功能性受体。SaOs-2细胞对VIP产生反应,cAMP增加。该效应迅速(2分钟),且在0.15 - 15 nM的VIP浓度范围内呈剂量依赖性,在1.4 nM时达到最大刺激的一半。SaOs-2细胞产生前列腺素E2(PGE2),对外源性PGE2产生反应,cAMP增加量约为VIP诱导增加量的三分之一。然而,VIP刺激的cAMP增加并未伴随可检测到的PGE2产生增加,且cAMP的增加不受环氧化酶抑制剂吲哚美辛的影响。用VIP预处理24小时的SaOs-2细胞对VIP的第二次急性刺激反应明显减弱,但仍保留对PGE2的反应能力。同样,用PGE2预处理可诱导对PGE2的同源脱敏,但对VIP刺激的cAMP增加无影响。这些反应模式与之前在器官培养的完整小鼠颅骨中描述的模式相似。用[125I]VIP进行的结合研究表明,SaOs-2细胞上存在针对VIP的特异性、可饱和、高亲和力受体。在37℃对[125I]VIP结合进行Scatchard分析得到一条曲线。基于两个独立结合位点的假设进行分析,高亲和力和低亲和力结合位点的Kd值分别为0.44和17 nM。每个细胞的高亲和力和低亲和力位点数量分别确定为8500和57000。[125I]VIP的结合受到两种相关肽促胰液素和PHI - 27的部分抑制,但不受甲状旁腺激素、降钙素或多种无关肽的抑制。我们得出结论,VIP对人SaOs-2细胞的作用与在完整小鼠颅骨中观察到的作用相似,并且这些细胞为研究VIP在骨中作用的初始步骤提供了一个良好的模型。